A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Dose escalation phase 1 study of PARP inhibitor PF-01367338 in combination with chemotherapy in adult patients with advanced solid tumors

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clovis Oncology, Inc.
• Treatments: Carboplatin; Poly(ADP-ribose) Polymerase Inhibitors; Rucaparib

Criteria

Inclusion Criteria:

• Patients with histologically confirmed solid tumors, Eastern Cooperative Oncology Group (ECOG) 0 or 1

• Patients with acceptable renal, hepatic, and bone marrow function

Exclusion Criteria:

• Symptomatic and/or unstable brain metastases,

• Any cancer treatment within 4 weeks from study entry